OncoMatch/Clinical Trials/NCT06930755
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Is NCT06930755 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including NMS-03305293 and Topotecan for ovarian cancer.
Treatment: NMS-03305293 · Topotecan — This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Excluded: BRCA1 mutation
Excluded: BRCA2 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: evidence based local standards of care
failed all evidence based local standards of care as per Investigator judgment
Cannot have received: PARP inhibitor
Exception: outside of approved indication and schedules
Prior therapy with PARP inhibitor, outside of approved indication and schedules
Cannot have received: topoisomerase inhibitor
Prior therapy with topoisomerase inhibitors including payloads of Antibody-Drug Conjugates (ADCs)
Cannot have received: wide-field radiotherapy
Exception: affecting at least 20 percent of the bone marrow
Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow
Cannot have received: anti-tumor treatment
Exception: within 2 weeks prior to treatment start or 5 half-lives, whichever is longer
Prior anti-tumor treatment within 2 weeks prior to treatment start or 5 half-lives, whichever is longer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OSF Saint Francis Medical Center · Peoria, Illinois
- Washington University School of Medicine in St. Louis · St Louis, Missouri
- Penn Medicine - Perelman Center for Advanced Medicine · Philadelphia, Pennsylvania
- Tennessee Oncology · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06930755 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor, topoisomerase inhibitor, wide-field radiotherapy disqualifies patients from enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages